Delays in protease inhibitor use in clinical practice
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
OBJECTIVE: To determine the clinical factors associated with delayed protease inhibitor initiation.
DESIGN: Chart review and telephone survey.
SETTING: General medicine practice at an academic medical center in Boston, Mass.
PATIENTS: One hundred ninety patients living with HIV and a viral load of more than 10,000 copies/ml.
MEASUREMENTS AND MAIN RESULTS: The main outcome measurement was time to first protease inhibitor prescription after first elevated HIV viral load (>10,000 copies/ml). In this cohort, 190 patients had an elevated viral load (median age 39; 87% male; 12% history of injection drug use; 63% AIDS; 53% with depression; 17% history of pneumocystis pneumonia; 54% CD4 <200). In Cox proportional hazards modeling, significant univariate correlates for delayed protease inhibitor initiation were higher CD4 cell count (hazard ratio [HR] 2.38 for CD4 200–500 compared with <200, 95% confidence interval [CI] 1.59, 3.57; and HR 8.33 for CD4 >500; 95% CI 2.63, 25.0), higher viral load (HR 0.43 for each 10-fold increase; 95% CI 0.31, 0.59), injection drug use (HR 2.08; 95% CI 1.05, 4.17), AIDS (HR 0.24; 95% CI 0.15, 0.36), and history of pneumocystis pneumonia (HR 0.32; 95% CI 0.21, 0.49). In multivariate models adjusted for secular trends in protease inhibitor use, factors significantly associated with delay of protease inhibitor initiation (p<.05) were higher CD4 cell count (for CD4 200–500, HR 2.63; 95% CI 1.61, 4.17; for CD4 >500, HR 11.11; 95% CI 3.57, 33.33), higher viral load (HR 0.66 for each 10-fold increase; 95% CI 0.45, 0.98), history of pneumocystis pneumonia (HR 0.57; 95% CI 0.37, 0.90), history of depression (HR 1.49; 95% CI 1.03, 2.13), and history of injection drug use (HR 2.70; 95% CI 1.35, 5.56).
CONCLUSIONS: HIV-infected patients with higher CD4 cell counts or a history of depression or history of injection drug use have significant and lengthy delays of protease inhibitor therapy. Although some delays may be clinically appropriate, enhancement of provider and patient education might prove beneficial. Further research should examine reasons for delays in protease inhibitor initiation and their appropriateness.
- O’Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996;276:105–10. CrossRef
- Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573–9.
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science. 1996;271:1582–6. CrossRef
- Cohen OJ, Pantaleo G, Holodniy M, et al. Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci USA. 1995;92:6017–21. CrossRef
- Carpenter CCJ, Fischl MA, Hammer SM, et al., for the International AIDS Society. Antiretroviral Therapy for HIV infection in 1996: recommendations of an international panel. JAMA. 1996;276:146–54. CrossRef
- Carpenter CCJ, Fischl MA, Hammer SM, et al., for the International AIDS Society. Antiretroviral Therapy for HIV infection in 1997: updated recommendations of the International AIDS Society—USA Panel. JAMA. 1997;277:1962–9. CrossRef
- Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145–53. CrossRef
- Williams A, Friedland G. Adherence, compliance, and HAART. AIDS Clinical Care. 1997;9:51–4,58.
- Safran C, Rury C, Rind DM, Taylor WC. A computer-based outpatient medical record for a teaching hospital. MD Comput. 1991;8:291–9. CrossRef
- Makadon HJ, Delbanco SF, Delbanco TL. Caring for people with AIDS and HIV infection in hospital-based primary care practice. J Gen Intern Med. 1990;5:446–50. CrossRef
- Fairfield KM, Eisenberg DM, Davis RB, Libman H, Phillips RS. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients. Arch Intern Med. 1998;158:2257–64. CrossRef
- Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariable Methods. Belmont, Calif: Duxbury Press; 1988.
- Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129:125–37.
- US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services. 1998;47(RR-5):43–82.
- Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1997:9 (No. 1).
- Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–60. CrossRef
- Detels R, Munoz A, McFarlane G, et al. Increased survival time to AIDS and death associated with use of combined therapy in the multicenter AIDS cohort study. Presented at the 5th Conference on Retroviral Opportunistic Infection, Feb 1–5, 1998. Abstract 115.
- McNaghten AD, Hanson DL, Jones JL, Ward JW, Dworkin MS. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. Presented at the 5th Conference on Retroviral Opportunistic Infection, Feb 1–5, 1998. Abstract 81.
- Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–6. CrossRef
- Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–9. CrossRef
- Mayne TJ, Vittinghoff E, Chesney MA, Barrett DC, Coates TJ. Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med. 1996;156:2233–8. CrossRef
- Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261–9. CrossRef
- Delays in protease inhibitor use in clinical practice
Journal of General Internal Medicine
Volume 14, Issue 7 , pp 395-401
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- protease inhibitors
- injection drug use
- Industry Sectors
- Author Affiliations
- 1. Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Libby 330, 330 Brookline Ave., 02215, Boston, MA
- 2. the Center for Alternative Medicine Research, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Mass